GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2013

NGM Inks Diabetes Deal with Janssen

  • NGM Biopharmaceuticals signed an agreement with Janssen Pharmaceuticals to discover and develop novel therapeutics for the potential treatment of type 2 diabetes and other metabolic diseases. NGM and Janssen will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the goal of advancing drug candidates that mimic the potential glucoregulatory effects of bariatric surgery on diabetes patients. Janssen will receive an exclusive worldwide license to develop, manufacture, and commercialize compounds resulting from the collaboration.

    Under the terms of the agreement, NGM will receive an up-front payment and research support for activities conducted in collaboration with Janssen. In addition, NGM is eligible to receive payments upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on product sales.

    In March 2012, NGM collaborated with Daiichi Sankyo in a similar deal to develop therapeutics that modulate beta-cell regeneration, for the treatment of type 1 and type 2 diabetes.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »